Authors
Latest:
Recognizing hereditary syndromes in renal cell carcinomaPatients may require specific diagnostic, surveillance, and therapeutic management.
Latest:
Low-intensity shockwave therapy, plasma injections efficacious for erectile dysfunctionSMSNA 2024 abstract data show shockwave therapies and platelet-rich plasma, either alone or in combination, may be promising treatments for ED.
Latest:
EBRT not linked to increased hematological toxicity for mCRPC treated with Ra-233Drug-related hematological treatment-emergent adverse events were proportionately similar between the EBRT cohort and the those who did not receive EBRT to the bone.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Considerations for palliative care in urologic oncologyBenefits include improved quality of life and symptom management.
Latest:
Physician Commentary: Do EHR upgrades really enhance patient care?"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.
Latest:
Considerations for choosing an AI scribe toolAI scribe solutions are one of the easiest technologies to deploy into existing workflows, writes Vadim Khazan.
Latest:
Key Takeaways on the Evolving NMIBC Treatment LandscapeThe panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
Latest:
EP. 1B: Advanced/Metastatic Prostate Cancer: Disease Overview, Treatment Strategies, and Unmet NeedsIn this companion article, Judd W. Moul, MD, of Duke University Medical Center, shares expert insights into factors affecting treatment decisions in metastatic hormone-sensitive and castration-resistant prostate cancer.
Latest:
Male sexual health and reproductive medicine: All that glitters is not gold"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.
Latest:
Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPC"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.
Latest:
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD.
Latest:
Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR AlterationPanelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.
Latest:
Understanding molecular phenotypes in RCC may help drive treatment decisionsBenjamin L. Maughan, MD, PharmD, highlights key studies presented at the 2024 ASCO Annual Meeting regarding biomarkers and the evolution of first-line treatments in renal cell carcinoma.
Latest:
GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical TrialFor the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.
Latest:
Expert compares Aquablation with TURP for treatment of BPH"The main benefit, I guess, for Aquablation over TURP, is the fact that the sexual side effects are much better when compared to TURP," says Mohamad Baker Berjaoui, MD.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Unmet Needs and Clinical Challenges for PSMA ImagingOliver Sartor, MD, discusses how unmet needs and clinical challenges for PSMA imaging in prostate cancer patients include standardizing interpretation criteria, addressing false negatives in certain tumor phenotypes, improving accessibility and cost-effectiveness, and developing strategies for patients with low PSMA expression or PSMA-negative disease.
Latest:
Upper tract urothelial carcinoma: An in-depth review for urologists"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.
Latest:
Hybrid approach to telehealth effective in rural communities“A hybrid telehealth approach expands access to specialized care, reduces travel burdens, promotes timely interventions, and enables continuous management of health conditions,” writes Kara Hartl, MD.
Latest:
Unmet Needs and Treatment Gaps in Prostate CancerThe panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
Latest:
ADT Treatment Considerations and Unmet Needs in Prostate CancerExperts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.
Latest:
Investigators characterize vibegron prescribing patterns for OAB"We found that the location that prescribers were registered in, as well as their fellowship training, was significantly associated with higher vibegron prescription rates,” says Grace Khaner.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Episode 3 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric ChallengesWayne Kuang, MD; and Matt T. Rosenberg, MD, discuss how overactive bladder presents with distinct pathophysiological mechanisms between genders, requires different diagnostic approaches when distinguishing from benign prostatic hyperplasia in men, impacts quality of life in older adults, benefits from early primary care intervention, and necessitates improved patient advocacy and educational initiatives for optimal management outcomes.
Latest:
Expert examines tech-driven burnout in healthcare“Health care technology has largely failed to deliver on its promise to make the management of patient care simpler, easier, and less stressful for clinicians,” writes Oron Afek.
Latest:
What role can automation play in solving the prior authorization issue?If automation can enhance efficiency and reduce provider dissatisfaction while improving patient health, there’s a strong case for introducing automation into the mix, writes industry expert Eric Demers.
Latest:
Tax deduction can offset your practice’s cost for new equipment and technologySection 179 of the IRS Tax Code allows businesses to deduct up to the full purchase price of qualified equipment, technology, software, and other qualifying purchases from their taxes within the same tax year.
